Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Cluster analysis and display of genome-wide expression patterns

Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 12,617 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works

Epidermal growth factor-related peptides and their receptors in human malignancies.

Salomon, D., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical reviews in oncology/hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,860 · see citing works

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605 · see citing works

Epithelial-Mesenchymal Transitions

Kang, Y., & Massagué, J. (2004) · Cell · doi:10.1016/j.cell.2004.07.011 · Cited by 1,526 · see citing works

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517 · see citing works

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · see citing works

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453 · see citing works

Somatic Mutations of the <i>HER2</i> Kinase Domain in Lung Adenocarcinomas

Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678 · see citing works

Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?

Thompson, E. W., & Newgreen, D. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0616 · Cited by 667 · see citing works

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

Pao, W. J., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 628 · see citing works

Cadherin Switch in Tumor Progression

Hazan, R. B., QIAO, R., Keren, R., Badano, I., & Suyama, K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.016 · Cited by 595 · see citing works

The Fallacy of Epithelial Mesenchymal Transition in Neoplasia

Jackson, D. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0699 · Cited by 531 · see citing works

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 508 · see citing works

Snail Induction of Epithelial to Mesenchymal Transition in Tumor Cells Is Accompanied by MUC1 Repression andZEB1 Expression

Guaita, S., Puig, I., Francı́, C., Garrido, M., Dominguez-Sola, D., Batlle, E., Sancho, E., Dedhar, S., de Herreros, A. G., & Baulida, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206400200 · Cited by 501 · see citing works

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 494 · see citing works

Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

Janne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405 · see citing works

Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431 Human Carcinoma Cells

Merlino, G. T., Xu, Y.-H., Ishii, S., Clark, A., Semba, K., Toyoshima, K., Yamamoto, T. S., & Pastan, I. H. (1984) · Science · doi:10.1126/science.6200934 · Cited by 401 · see citing works

E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases

Qian, X., Karpova, T., Sheppard, A. M., McNally, J., & Lowy, D. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600136 · Cited by 396 · see citing works

Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

Tracy, S. I., Mukohara, T., Hansen, M., Meyerson, M. M., Johnson, B. E., & Janne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 368 · see citing works

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 329 · see citing works

High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non–Small-Cell Lung Cancer

Bremnes, R. M., Veve, R., Gabrielson, E. W., Hirsch, F. R., Barón, A. E., Bemis, L., Gemmill, R. M., Drabkin, H. A., & Franklin, W. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.159 · Cited by 281 · see citing works

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7022 · Cited by 281 · see citing works

Epimorphin: A mesenchymal protein essential for epithelial morphogenesis

Hirai, Y., Takebe, K., Takashina, M., Kobayashi, S., & Takeichi, M. (1992) · Cell · doi:10.1016/0092-8674(92)90448-l · Cited by 221 · see citing works

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.409 · Cited by 204 · see citing works

Expression profiling — best practices for data generation and interpretation in clinical trials

The Tumor Analysis Best Practices Working Group (2004) · Nature Reviews Genetics · doi:10.1038/nrg1297 · Cited by 203 · see citing works

Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance.

Kase, S., Sugio, K., Yamazaki, K., Okamoto, T., Yano, T., & Sugimachi, K. (2000) · PubMed · Cited by 199 · see citing works

WNT7a induces E-cadherin in lung cancer cells

Ohira, T., Gemmill, R. M., Ferguson, K., Kusy, S., Roche, J., Brambilla, E. M., Zeng, C. X., Barón, A. E., Bemis, L., Erickson, P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734137100 · Cited by 182 · see citing works

TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Herbst, R. S., Prager, D., Hermann, R., Miller, V. A., Fehrenbacher, L., Hoffman, P. C., Johnson, B. E., Sandler, A. B., MASS, R. D., & Johnson, D. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7011 · Cited by 146 · see citing works

HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells

Hirata, A., Hosoi, F., Miyagawa, M., Ueda, S.-I., Naito, S., Fujii, T., Kuwano, M., & Ono, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2748 · Cited by 109 · see citing works

E-Cadherin Binding Modulates EGF Receptor Activation

Fedor‐Chaiken, M., Hein, P. W., Stewart, J. C., Brackenbury, R. W., & Kinch, M. S. (2003) · Cell Communication & Adhesion · doi:10.1080/cac.10.2.105.118 · Cited by 107 · see citing works

Preclinical studies with Erlotinib (Tarceva)

Akita, R. W., & Sliwkowski, M. X. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70011-6 · Cited by 95 · see citing works

No one-way street: Cross-talk between E-cadherin and receptor tyrosine kinase (RTK) signaling—A mechanism to regulate RTK activity

Andl, C. D., & Rustgi, A. K. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.1.1431 · Cited by 84 · see citing works

Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

Hirsch, F. R., & Witta, S. E. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000155059.39733.9d · Cited by 68 · see citing works

Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry

Deeb, G., Wang, J., Ramnath, N., Slocum, H. K., Wiseman, S. M., Beck, A. F., & Tan, D. (2004) · Modern Pathology · doi:10.1038/modpathol.3800041 · Cited by 68 · see citing works

Benefits of adjuvant chemotherapy in high-grade gliomas

DeAngelis, L. M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.037 · Cited by 30 · see citing works

Expression of E-cadherin and beta-catenin in human non-small cell lung cancer: Clinical significance and prognosis

Kase, S., Sugio, K., Yamazaki, K., Okamoto, T., Koga, T., Ondo, K., Yamaguchi, M., Shoji, F., & Sugimachi, K. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80667-4 · Cited by 23 · see citing works

Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21

Tsao, M., Sakurada, A., Lorimer, I. A. J., Cutz, J.-C., Kamel‐Reid, S., Squire, J. A., Ding, K., Frank, R., Seymour, L., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7007 · Cited by 17 · see citing works

Characterization of HER1 (c-erbB1) Status in Locally Advanced Breast Cancer Using Fluorescence in situ Hybridization and Immunohistochemistry

Corzo, C., Tusquets, I., Salido, M., Corominas, J. M., Bellet, M., Suarez, M., Baró, T., Fabregat, X., Serrano, S., & Solé, F. G. (2005) · Tumor Biology · doi:10.1159/000084183 · Cited by 15 · see citing works

Epithelial-Mesenchymal Transitions in Development and Disease

Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · see citing works

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · see citing works

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

Gupta, P. B., Önder, T. T., Jiang, G., Tao, K. X., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,386 · see citing works

Lung Cancer

Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,388 · see citing works

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027 · see citing works

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059 · see citing works

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., Gallick, G. E., Logsdon, C. D., McConkey, D. J., & Choi, W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2819 · Cited by 866 · see citing works

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 804 · see citing works

The great escape: tumour cell plasticity in resistance to targeted therapy

Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 759 · see citing works

Involvement of Members of the Cadherin Superfamily in CancerPreprint

Berx, G., & Roy, F. M. V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003129 · Cited by 706 · see citing works

Epithelial–mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic

Voulgari, A., & Pintzas, A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.002 · Cited by 672 · see citing works

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R. L., Turnbull, J. D., Herold, C. I., Marcom, P. K., George, D. J., & García-Blanco, M. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0490 · Cited by 646 · see citing works

Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression

Lo, H., Hsu, S.-C., Xia, W., Cao, X., Shih, J., Wei, Y., Abbruzzese, J. L., Hortobágyi, G. N., & Hung, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0575 · Cited by 625 · see citing works

Molecular analysis of circulating tumour cells—biology and biomarkers

Krebs, M., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 620 · see citing works

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Tótpál, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 607 · see citing works

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

Roock, W. D., de Vriendt, V., Normanno, N., Ciardiello, F., & Tejpar, S. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70209-6 · Cited by 605 · see citing works

EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness

Sànchez‐Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 520 · see citing works

TGF-β Signaling in Lung Health and Disease

Saito, A., Horie, M., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082460 · Cited by 501 · see citing works

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476 · see citing works

Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation

Yao, D., Dai, C., & Peng, S. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0568 · Cited by 455 · see citing works

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445 · see citing works

The tumor microenvironment is a dominant force in multidrug resistance

Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443 · see citing works

Cancer stem cells and chemoresistance: The smartest survives the raid

Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 433 · see citing works

miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

Adam, L., Zhong, M., Choi, W., Wei, Q., Nicoloso, M. S., Arora, A., Calin, G. A., Wang, H., Siefker-Radtke, A. O., McConkey, D. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2245 · Cited by 410 · see citing works

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398 · see citing works

TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389 · see citing works

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70385-0 · Cited by 374 · see citing works

Epithelial–mesenchymal transition and tumour invasion

Guarino, M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.011 · Cited by 369 · see citing works

Early events in cell adhesion and polarity during epithelial-mesenchymal transition

Huang, R. Y., Guilford, P., & Thiery, J. P. (2012) · Journal of Cell Science · doi:10.1242/jcs.099697 · Cited by 369 · see citing works

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Ladanyi, M., & Pao, W. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801018 · Cited by 365 · see citing works

Characterizing deformability and surface friction of cancer cells

Byun, S., Son, S., Amodei, D., Cermak, N., Bagnall, J., Kang, J. H., Hecht, V. C., Winslow, M. M., Jacks, T., Mallick, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218806110 · Cited by 364 · see citing works

EMT‐associated microRNAs and their roles in cancer stemness and drug resistance

Pan, G., Liu, Y., Shang, L., Zhou, F., & Yang, S. (2021) · 癌症：英文版 · doi:10.1002/cac2.12138 · Cited by 362 · see citing works

The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies

Hollier, B. G., Evans, K., & Mani, S. A. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9110-3 · Cited by 352 · see citing works

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

Corkery, B., Crown, J. P., CLYNES, M. M., & O’Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348 · see citing works

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance

Wang, Z. P., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 342 · see citing works

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

Marcucci, F., Stassi, G., & Maria, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 340 · see citing works

Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer

Gunasinghe, N. P. A. D., Wells, A. H., Thompson, E. W., & Hugo, H. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9377-5 · Cited by 339 · see citing works

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

Jolly, M. K., Somarelli, J. A., Sheth, M. U., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S., Bapat, S. A., Rangarajan, A., & Levine, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.007 · Cited by 327 · see citing works

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers

Sabbah, M., Emami, S., Redeuilh, G., Julien-Grille, S., Prevost, G. P., Zimber, A., Ouelaa-Benslama, R., Bracke, M., Wever, O. D., & Gespach, C. P. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.07.001 · Cited by 322 · see citing works

Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress

Feng, Y., Sokol, E. S., Fitz, C. D. V., Sanduja, S., Claessen, J. H. L., Proia, T. A., Jin, D. X., Reinhardt, F., Ploegh, H. L., Wang, Q., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0945 · Cited by 323 · see citing works

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · see citing works

The EMT regulator slug and lung carcinogenesis

Shih, J.-Y., & Yang, P. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr110 · Cited by 315 · see citing works

Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells

Fuchs, B. C., Fujii, T., Dorfman, J. D., Goodwin, J. M., Zhu, A. X., Lanuti, M. D., & Tanabe, K. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2460 · Cited by 308 · see citing works

Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung Cancer

Ceppi, P., Mudduluru, G., Kumarswamy, R., Rapa, I., Scagliotti, G. V., Papotti, M. G., & Allgayer, H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0052 · Cited by 304 · see citing works

Cyclooxygenase-2–Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non–Small Cell Lung Cancer

Dohadwala, M., Yang, S.-C., Luo, J., Sharma, S. P., Batra, R. K., Huang, M., Lin, Y., Goodglick, L., Krysan, K., Fishbein, M. C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3635 · Cited by 283 · see citing works

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 280 · see citing works

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

Suda, K., Tomizawa, K., Fujii, M., Murakami, H., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318216ee52 · Cited by 277 · see citing works

Emerging role of tumor cell plasticity in modifying therapeutic response

Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 274 · see citing works

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A., & Raben, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0138 · Cited by 270 · see citing works

EMT : Present and future in clinical oncology

Santamarı́a, P. G., Moreno‐Bueno, G., Portillo, F., & Cano, A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12091 · Cited by 259 · see citing works

Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor–β Signaling

Shintani, Y., Maeda, M., Chaika, N. V., Johnson, K. R., & Wheelock, M. J. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0071oc · Cited by 259 · see citing works

A Convergence-Based Framework for Cancer Drug Resistance

Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258 · see citing works

Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression?

Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253 · see citing works

Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-κB Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma

Chung, C. H., Parker, J. S., Ely, K., Carter, J., Yi, Y., Murphy, B. A., Ang, K. K., El‐Naggar, A. K., Zanation, A. M., Cmelak, A. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1213 · Cited by 250 · see citing works

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives

Saunders, N. A., Simpson, F., Thompson, E. W., Hill, M. M. C., Endo‐Munoz, L., Leggatt, G. R., Minchin, R. F., & Guminski, A. D. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101131 · Cited by 249 · see citing works

Molecular Biology of Lung Cancer: Clinical Implications

Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 247 · see citing works

Targeting Notch signaling pathway to overcome drug resistance for cancer therapy

Wang, Z. P., Li, Y., Ahmad, A., Azmi, A. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.06.001 · Cited by 233 · see citing works

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

Ye, X., Li, Y., Stawicki, S. S., Couto, S. S., Eastham‐Anderson, J., Kallop, D. Y., Weimer, R. M., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 231 · see citing works

Cancer drug resistance induced by EMT: novel therapeutic strategies

Rivas, J. D. L., Brozović, A., Izraely, S., Casas-Pais, A., Witz, I. P., & Figueroa, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03063-7 · Cited by 232 · see citing works

Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front

Wever, O. D., Pauwels, P., Craene, B. D., Sabbah, M., Emami, S., Redeuilh, G., Gespach, C. P., Bracke, M., & Berx, G. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0464-1 · Cited by 229 · see citing works

Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression

McConkey, D. J., Lee, S., Choi, W., Tran, M., Majewski, T., Lee, S., Siefker-Radtke, A. O., Dinney, C. P., & Czerniak, B. A. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.04.008 · Cited by 224 · see citing works

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

Rho, J. K., Choi, Y. J., Lee, J. K., Ryoo, B., Na, I. I., Yang, S. H., Kim, C. H., & Lee, J. C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.017 · Cited by 220 · see citing works

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216 · see citing works

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer

Tulchinsky, E. M., Demidov, O. N., Kriajevska, M. V., Barlev, N. A., & Имянитов, Е. Н. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.003 · Cited by 209 · see citing works

Molecular biology of lung cancer: Clinical implications

Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 210 · see citing works

Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression

Wendt, M. K., Tian, M., & Schiemann, W. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1199-1 · Cited by 212 · see citing works

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

Buck, E. A., Eyzaguirre, A., Rosenfeld-Franklin, M., Thomson, S., Mulvihill, M. J., Barr, S. M., Brown, E., O’Connor, M., Yao, Y., Pachter, J. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6720 · Cited by 211 · see citing works

A systems view of epithelial–mesenchymal transition signaling states

Thomson, S., Petti, F., Sujka-Kwok, I., Mercado, P., Bean, J. M., Monaghan, M., Seymour, S. L., Argast, G. M., Epstein, D. M., & Haley, J. D. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9367-3 · Cited by 210 · see citing works

Drug resistance to targeted therapies: Déjà vu all over again

Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 211 · see citing works

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Sang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0440 · Cited by 207 · see citing works

miR-200bc/429 cluster targets PLCγ1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer

Uhlmann, S., Zhang, J., Schwäger, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., Ward, A., Korf, U., Wiemann, S., & Şahin, Ö. (2010) · Oncogene · doi:10.1038/onc.2010.201 · Cited by 199 · see citing works

Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells

Heery, R., Finn, S. P., Cuffe, S. D., & Gray, S. G. (2017) · Cancers · doi:10.3390/cancers9040038 · Cited by 196 · see citing works

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 198 · see citing works

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Barr, S. M., Thomson, S., Buck, E. A., Russo, S. M., Petti, F., Sujka-Kwok, I., Eyzaguirre, A., Rosenfeld-Franklin, M., Gibson, N. W., Miglarese, M. R., et al. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9121-7 · Cited by 197 · see citing works

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Witta, S. E., Jotte, R. M., Konduri, K., Neubauer, M., Spira, A. I., Ruxer, R. L., Varella‐Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 197 · see citing works

Differences in Survival Among Patients With Sarcomatoid Carcinoma, Carcinosarcoma and Urothelial Carcinoma of the Bladder

Wright, J. L., Black, P. C., Brown, G. A., Porter, M. P., Kamat, A. M., Dinney, C. P., & Lin, D. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.038 · Cited by 195 · see citing works

Epithelial mesenchymal transition and lung cancer.

Xiao, D., & He, J. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.7 · Cited by 193 · see citing works

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Buck, E. A., Eyzaguirre, A., Barr, S. M., Thompson, S. D., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P. J., & Haley, J. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0462 · Cited by 191 · see citing works

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

Thomson, S., Petti, F., Sujka-Kwok, I., Epstein, D. M., & Haley, J. D. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9200-4 · Cited by 190 · see citing works

MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells

Kitamura, K., Seike, M., Okano, T., Matsuda, K., Miyanaga, A., Mizutani, H., Noro, R., Minegishi, Y., Kubota, K., & Gemma, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0448 · Cited by 189 · see citing works

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

Chung, J.-H., Rho, J. K., Xu, X., Lee, J. S., Yoon, H. I., Lee, C. T., Choi, Y. J., Kim, H.-R., Kim, C. H., & Lee, J. C. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.011 · Cited by 186 · see citing works

Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition

Miele, L., Espinoza, I. C., Pochampally, Watabe, & Xing, F. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36162 · Cited by 185 · see citing works

Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options

Yousefi, M., Bahrami, T., Salmaninejad, A., Nosrati, R., Ghaffari, P., & Ghaffari, S. H. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0345-5 · Cited by 177 · see citing works

Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer

Nurwidya, F., Takahashi, F., Murakami, A., & Takahashi, K. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.151 · Cited by 177 · see citing works

Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line

Pirozzi, G., Tirino, V., Camerlingo, R., Franco, R., Rocca, A. L., Liguori, E., Martucci, N., Paino, F., Normanno, N., & Rocco, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021548 · Cited by 172 · see citing works

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells

Cao, M., Seike, M., Soeno, C., Mizutani, H., Kitamura, K., Minegishi, Y., Noro, R., Yoshimura, A., Cai, L., & Gemma, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1535 · Cited by 168 · see citing works

Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 168 · see citing works

ERK1/2 Blockade Prevents Epithelial–Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition

Buonato, J. M., & Lazzara, M. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4721 · Cited by 163 · see citing works

Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy

Anwar, S., Shamsi, A., Mohammad, T., Islam, A., & Hassan, M. I. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188568 · Cited by 165 · see citing works

Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial–mesenchymal transition of breast cancer cells

Li, Q.-Q., Chen, Z.-Q., Cao, X.-X., Xu, J., Xu, J.-W., Chen, Y.-Y., Wang, W.-J., Chen, Q., Tang, F., Liu, X.-P., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.103 · Cited by 165 · see citing works

Mechanisms of Acquired Resistance to Targeted Cancer Therapies

Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 163 · see citing works

Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Chang, T., Tsai, M.-F., Su, K., Wu, S.-G., Huang, C.-P., Yu, S., Yu, Y., Lan, C., Yang, C.-H., Lin, S.-B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 162 · see citing works

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma

Hatakeyama, H., Cheng, H., Wirth, P. S., Counsell, A., Marcrom, S., Wood, C. B., Pohlmann, P. R., Gilbert, J., Murphy, B. A., Yarbrough, W. G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012702 · Cited by 163 · see citing works

Role of Epidermal Growth Factor Receptor Pathway–Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Cohen, E. E. W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4577 · Cited by 160 · see citing works

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Huang, C.-P., Tsai, M., Chang, T., Tang, W.-C., Chen, S., Lai, H.-H., Lin, T., Yang, J. C., Yang, P., Shih, J., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.021 · Cited by 162 · see citing works

DNA methylation based biomarkers: Practical considerations and applications

Kit, A. H., Nielsen, H. M., & Tost, J. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.014 · Cited by 160 · see citing works

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK

Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.001 · Cited by 156 · see citing works

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 162 · see citing works

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Thomson, S., Buck, E. A., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N. W., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663 · see citing works

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Thomson, S., Petti, F., Sujka-Kwok, I., Buck, E. A., Barr, S. M., Miglarese, M. R., & Haley, J. D. (2007) · Molecular Cancer Therapeutics

Abstract 5063: Preclinical evaluation of an EMT multi-gene biomarker index for predicting response to inhibitors of EGFR and IGF1R

Argast, G. M., Bean, J. M., Wang, J., O'Connor, M., Feng, B., Nicoletti, R., Lerner, L. R., Heyer, J., Chiu, M. I., Robinson, M. O., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5063

Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.

Pool, M. D., Fidler, M. J., Basu, S., Mahon, B., Buckingham, L. E., Walters, K. K., Batus, M., Hensing, T. A., Borgia, J. A., & Bonomi, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e19117

P3-015: Clinicopathologic features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer

Zhou, C., Deng, Q., & Su, C. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283501.96516.b4